Resveratrol and epigallocatechin gallate: in vitro study of two natural compounds for endometriosis treatment and their impact on estrogen action.

OLIVARES C.; BARAÑAO RI; MADANES D; MC CORMACK B.; BILOTAS M.; FERELLA L; RICCI A.

C.A.B.A.

Congreso; REUNION CONJUNTA DE SOCIEDADES DE BIOCIENCIAS; 2017

SAB-SAIC-SAIB-SAI-SAA-SAH-SAP-SAB-SAFE-SAFIS

It is known from our previous studies that resveratrol (RES) and epigallocatechin gallate (EGCG), two natural polyphenols with well-known anticarcinogenic properties, have a strong antiproliferative and proapoptotic activity both in-vivo and in-vitro in experimental endometriosis. Moreover, we recently showed the participation of PI3K/AKT pathway in endometriosis, both in patients and experimental models. The aim to this work was to study the in-vitro effect of these compounds on aromatase and estrogen receptor α expression and to evaluate the impact of RES on endometrial cells proliferation induced by E2. Human endometrial epithelial (ECC-1) and stromal (T-HESC) cell lines were cultured according to standard protocols and were stimulated with different doses of RES (50 and 100µM) or EGCG (20 and 40µM) for 24h. Cell proliferation was assessed using the WST-1 reduction kit, in presence or absence of E2 and/or the estrogen receptor antagonist ICI 182,780. Levels of aromatase and estrogen receptor α expression were assessed by Western Blot. Both doses of RES inhibited aromatase expression (p